QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
Free Trial

Ironwood Pharmaceuticals (IRWD) Stock Forecast & Price Target

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)
Free irwd Stock Alerts
$7.82
+0.03 (+0.39%)
(As of 01:10 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Ironwood Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$19.80
153.20% Upside
High Forecast$22.00
Average Forecast$19.80
Low Forecast$14.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.80$19.80$20.60$14.67
Predicted Upside153.20% Upside81.45% Upside98.44% Upside27.28% Upside
Get Ironwood Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

IRWD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IRWD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ironwood Pharmaceuticals Stock vs. The Competition

TypeIronwood PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside154.17% Upside882.30% Upside11.22% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/1/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$20.00 ➝ $14.00+54.02%
2/16/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$20.00 ➝ $21.00+41.22%
1/17/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$21.00+78.88%
11/9/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$21.00+127.52%
9/28/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$22.00+128.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:31 PM ET.

IRWD Price Target - Frequently Asked Questions

What is Ironwood Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Ironwood Pharmaceuticals stock is Buy based on the current 5 buy ratings for IRWD. The average twelve-month price prediction for Ironwood Pharmaceuticals is $19.80 with a high price target of $22.00 and a low price target of $14.00. Learn more on IRWD's analyst rating history.

Do Wall Street analysts like Ironwood Pharmaceuticals more than its competitors?

Analysts like Ironwood Pharmaceuticals more than other Medical companies. The consensus rating for Ironwood Pharmaceuticals is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how IRWD compares to other companies.

Does Ironwood Pharmaceuticals's stock price have much upside?

According to analysts, Ironwood Pharmaceuticals's stock has a predicted upside of 81.45% based on their 12-month stock forecasts.

What analysts cover Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has been rated by Craig Hallum, Piper Sandler, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:IRWD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency